Postdoctoral position in development of radiopharmaceuticals

Published: 2022-06-17

Uppsala University is a comprehensive research-intensive university with a strong international standing. Our ultimate goal is to conduct education and research of the highest quality and relevance to make a long-term difference in society. Our most important assets are all the individuals whose curiosity and dedication make Uppsala University one of Sweden’s most exciting workplaces. Uppsala University has over 54,000 students, more than 7,500 employees and a turnover of around SEK 8 billion.

The Department of Medicinal Chemistry at Uppsala University is a strong and international research environment. The department has about 85 employees and here, doctoral students, teachers, researchers and administrators work closely together in a creative and open environment. More information about the department can be found at

The Theranostic group is looking for an outstanding postdoc in development of radiopharmaceuticals, with excellent scientific track-record and organizational skills, to work in a leading research environment with scientists of diverse and international background.

The position will be based in the Theranostic research group (Prof. A.Orlova) at the Department of Medicinal Chemistry at Uppsala University. The research group focuses on development of molecular targeted radiopharmaceuticals for diagnostic imaging and therapy of cancer. The research group consists of one senior and two junior scientists, with diverse international backgrounds.

Read more about our benefits and what it is like to work at Uppsala University

Project description
We are looking for a postdoc in development of radiolabelled theranostic agents for diagnostic and treatment of prostate cancer. The project is a part of a larger program focusing on imaging and therapy of prostate cancer using antagonist to gastrin releasing peptide receptor (GRPR), PSMA inhibitors and targeting scaffold proteins. The overall goal is to investigate factors influencing targeting properties of the protein based targeting agent and their excretion pathways. The project involves development and optimisation of labelling methods for gallium-68, indium-111, technetium-99m, luthetium-177 and other radionuclides, characterisation of labelled proteins and their in vitro and in vivo investigation. The exact description of the tasks depends on the individual skills and research interests of the applicant.

The main duties of the applicant will be to participate in and lead research projects. Your work will include radiolabeling, identity and stability determination by HPLC, ITLC, SDS, and radioautogaraphy, work with living cell cultures and frozen/fixed tissue samples, participation in in vivo and imaging experiments. Evaluation, analyses and presentation of obtained data is also included. The work duties can also include supervision of students, teaching and other departmental duties (no more than 20%).

We welcome applications from candidates that have (or soon will have) a PhD degree in medical, pharmaceutical or biological sciences or related subject, within a maximum of three (3) years before the final application date. During certain circumstances, an earlier PhD can be acceptable. Certain circumstances include leave due to illness, parental leave, work in trade unions, etc.

The applicant must have excellent skills in communication and teamwork, and must have a strong documented background in both radiolabeling and pre-clinical evaluation of radiolabeled  peptides/proteins. Fluency in both written and spoken English is an absolute prerequisite.

The applicant is expected to work independently and be able to take own initiatives. The assessment of applications is based primarily on the applicant’s ability to conduct independent research based on scientific skill.

Additional qualifications
FELACA C certificate (or equal education), publications in the field of preclinical development of (protein based) radiopharmeceuticals, and experience with microPET/SPECT/CT/MRI are advantageous.

Instructions for Application
The application should be written in English or Swedish and contain a cover letter (max 1 A4), a CV with publication list, as well as copies of certificates of higher academic degrees. Please also provide the contact details (name, e-mail, phone number) for at least two referee.

Selection process
Selection of candidates is based on qualifications, previous experience, and personal suitability.

About the employment
The employment is a temporary position according to central collective agreement. Scope of employment 100%. Starting date as agreed or at the latest 2023-02-01. Placement: Uppsala.

For further information about the position, please contact: Professor Anna Orlova, and Head of department Anders Karlén (

Please submit your application by 15 July 2022, UFV-PA 2022/2402.

Are you considering moving to Sweden to work at Uppsala University? Find out more about what it´s like to work and live in Sweden.

Please do not send offers of recruitment or advertising services.

Submit your application through Uppsala University’s recruitment system.

Deadline: 2022-07-15 at 23:59
Unit: Department of Medicinal Chemistry

Read the job description at the university homepage or apply.

Post expires on Friday July 15th, 2022